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Abstract: The anticancer efficacy of photodynamic therapy
(PDT) is limited due to the hypoxic features of solid tumors.
We report synergistic PDT/chemotherapy with integrated
tandem Fenton reactions mediated by ovalbumin encapsula-
tion for improved in vivo anticancer therapy via an enhanced
reactive oxygen species (ROS) generation mechanism. O2C
produced by the PDT is converted to H2O2 by superoxide
dismutase, followed by the transformation of H2O2 to the
highly toxic COH via Fenton reactions by Fe2+ originating from
the dissolution of co-loaded Fe3O4 nanoparticles. The PDT
process further facilitates the endosomal/lysosomal escape of
the active agents and enhances their intracellular delivery to the
nucleus—even for drug-resistant cells. Cisplatin generates O2C
in the presence of nicotinamide adenine dinucleotide phos-
phate oxidase and thereby improves the treatment efficiency by
serving as an additional O2C source for production of COH
radicals. Improved anticancer efficiency is achieved under both
hypoxic and normoxic conditions.
Introduction
Cancer has been one major threat to human health for
centuries.[1] Various anticancer therapies including chemo-
therapy, radiotherapy, chemodynamic therapy, and photo-
dynamic therapy (PDT) have been developed.[2] However,
treatment with a single therapy generally shows limited
efficacy due to the tumor heterogeneity.[3] Thus multimodal
therapies that combine different treatment approaches have
been broadly exploited. They show higher treatment effi-
ciency because the active compounds with different thera-
peutic mechanisms could act synergistically by targeting
multiple sites in the cell.[4] In particular, the combination of
PDT with chemotherapy presents unique advantages[5]
because the generated reactive oxygen species (ROS) directly
damage the tumor issues[6] and destroy the endosomes and
lysosomes to facilitate the intracellular delivery of drugs to
the targets such as nucleus, mitochondria, and microtubules.[7]
More importantly, ROS can reduce the drug resistance
developed in chemotherapy by damaging the DNA through
strong oxidation, and these damages could not be easily
repaired by the drug-resistance DNA repair enzymes.[8]
In spite of the promising anticancer applications of
combined PDT and chemotherapy, the hypoxic feature of
the solid tumors severely limits their efficacies.[9] This is
because the generation of ROS by traditional photosensi-
tizers relies highly on the oxygen tension of the local
microenvironment.[10] Moreover, PDT can result in more
severe tumor hypoxia by consuming oxygen, leading to the
expression of P-glycoprotein (P-gp) that prevents the cellular
uptake of anticancer drugs.[11] Several strategies have been
proposed to increase oxygen perfusion in the tumor micro-
environment,[12] such as the oxygen delivery systems (e.g.
artificial cells[13] and perfluorocarbon nanosystems[14]) and
oxygen self-supplement systems that are based on biological
or chemical reactions (e.g. catalase, MnO2, and CaO2).
[15]
However, these approaches only resulted in limited improve-
ment of PDT efficiency due to the rapid consumption and
slow diffusion of oxygen. Moreover, complex fabrication
processes are often required.[10a] Thus, developing a low
oxygen-demanding PDT system is essential for an efficient
photodynamic/chemical combination therapy, which has been
rarely reported.[16]
To this regard, we developed here a low O2 consumption
type I PDT/chemotherapy combination system with integrat-
ed tandem Fenton reactions aiming to an enhanced ROS
generation for improved anticancer therapy. Biodegradable
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ovalbumin nanocapsules (OVA-NCs) were synthesized as
nanocarriers for in vivo tumor targeted delivery of the active
agents through enhanced permeability and retention (EPR)
effect. The core–shell structure of the nanocapsules provides
a high encapsulation efficiency for multiple payloads in the
interior and payloads are selectively released upon biodegra-
dation of the shell. Three functional components (photo-
sensitizer, drug, and the Fenton catalyst) were co-encapsu-
lated in the PEGylated OVA-NCs (Scheme 1a). The Nile
blue with S-substitution (NBS), as the photosensitizer, is able
to generate ROS via type I photoreactions under red light
(656 nm) even under severe hypoxic environment (2% O2,
Scheme 1b).[17] The PDT produced O2C is partially converted
to H2O2 by superoxide dismutase (SOD), and followed with
the transformation of H2O2 to the highly toxic COH via Fe2+
mediated Fenton reactions that are enabled by the dissolution
of co-loaded Fe3O4 NPs within the cancer cells. Cisplatin is
a Food and Drug Administration (FDA)-approved anticancer
drug that possesses nuclear DNA crosslinking ability, thus can
restrain cell division. Moreover, cisplatin generates O2C in the
presence of nicotinamide adenine dinucleotide phosphate
oxidase (NOX). The generated O2C can also be partially
consumed to produce toxic COH radicals, thus cisplatin can
potentially improve the therapeutic efficiency by serving as an
additional ROS source.[17] The generated ROS from the
nanocapsules can induce cell apoptosis which also benefits for
endosomal/lysosomal escape of the active agents. Notably, the
intracellular SOD can catalyze partial O2
C to form hydrogen
peroxide (H2O2) and O2. Besides, O2 is also released from
Fenton reactions. Thus, the benefit of the system is that, at
least in part, the oxygen is recyclable, which facilitates the
enhancement of the anti-hypoxia performance.[18] Therefore,
this multifunctional nanomedicine is designed to synergisti-
cally improve the anticancer efficiency via the combination of
type I PDT and chemotherapy under both normoxic and
hypoxic conditions. Moreover, this nanoencapsulation strat-
egy provides a versatile platform for the flexible combination
of different therapies for biomedical applications.
Results and Discussion
Encapsulation of functional PDT/chemotherapy/Fenton reaction
reagents in the OVA-NCs
We synthesized biodegradable protein nanocapsules com-
prising an aqueous core and a crosslinked ovalbumin shell
through an interfacial polyaddition reaction in an inverse
(water-in-oil) miniemulsion. Hydrophilic therapeutic agents
were first dissolved or dispersed in an aqueous phase, which
was then emulsified in cyclohexane as the continuous phase.
The formed aqueous nanodroplets were stabilized with
a block copolymer surfactant P(E/B-b-EO). The crosslinker
2,4-toluene diisocyanate was then added to this miniemulsion.
A polyaddition reaction between the hydroxyl and amino
groups of ovalbumin and isocyanate groups of the crosslinker
took place at the nanodroplet-cyclohexane interface, result-
ing in water-insoluble nanocontainers with a densely cross-
linked polypeptide shell. Nanocapsules prepared in cyclohex-
ane were then transferred to an aqueous medium with the
stabilization by a PEG-based surfactant Lutensol AT50 for
enhanced colloidal stability in the blood.
For achieving a combined PDT and chemotherapy with
integrated Fenton reactions, three therapeutic reagents (a
photosensitizer NBS, Fe3O4 NPs for Fenton reactions, and an
anticancer drug cisplatin) need to be encapsulated simulta-
neously in the same nanocapsule. The NBS has a good
solubility in water hence it can be directly dissolved in the
water phase. The Fe3O4 NPs were synthesized by a co-
precipitation approach.[19] The obtained Fe3O4 NPs were
capped with hydrophobic oleic acid. Therefore, these NPs
were further transferred into an aqueous solution and were
stabilized by poly(vinyl alcohol) (see details in the Exper-
imental Section). The co-encapsulation of cisplatin was
challenging because of its very low solubility in water. Thus,
we added an additional water-miscible solvent (DMSO) to
the aqueous phase. Cisplatin has a good solubility in DMSO
at a concentration of 20 mgmL1, while ovalbumin does not
dissolve in DMSO. In this case, a mixture solvent of water and
Scheme 1. Illustration of a) the structure of the OVA-NCs containing photosensitizer, Fe3O4 NPs, and cisplatin. b) Targeted delivery of the OVA-
NCs in the hypoxia tumor site via EPR effect. c) The mechanism of the PDT/chemotherapy combination therapy with integrated tandem Fenton
reactions in the intracellular environment.
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DMSO at a proper ratio is important to dissolve all the
reagents and the ovalbumin. Finally, the optimized volume
ratio of DMSO and water was determined to be 1:1, which
allowed us to dissolve 5 mg cisplatin, 5 mg NBS, and 50 mg
ovalbumin, and to disperse 8 mg Fe3O4 NPs in 500 mL of the
water/DMSO mixture. The sample is denoted as FePt-
NBS@OVA. Nanocapsules containing only Fe3O4, Fe3O4
NPs plus cisplatin, Fe3O4 NPs plus NBS were prepared as
control groups, which are denoted as Fe@OVA, FePt@OVA,
and FeNBS@OVA, respectively. The final concentrations of
payloads in the samples are listed in Table 1.
The four nanocapsule formulations with various combi-
nations of payloads have hydrodynamic diameters around
300 nm and z-potentials of 25–35 mV (Table 1). This posi-
tively charged surface is due to the amino groups from lysine
of ovalbumin as well as the hydrolyzed unreacted isocyanate
groups from the diisocyanate crosslinker after the transfer of
nanocapsules to water. Core-shell morphology of the nano-
capsules (FePtNBS@OVA) was observed by using scanning
(SEM) and transmission electron microscopy (TEM) (Figur-
es 1a,b). The nanocapsules dispersions were stable in water
during a measuring time of 30 days in our study (Figure 1c).
The core–shell structure and highly crosslinked polypeptide
shell are beneficial for suppressing nonspecific release of
payloads. No leakage of NBS was detected after dialyzing the
samples in water for 30 h (Figure 1d). The degradability of
OVA-NCs was investigated by incubating the nanocapsules
with serine protease trypsin. Continuous release of NBS from
samples FeNBS@OVA and FePtNBS@OVA were observed
upon incubation with trypsin (Figure 1d), showing the
preserved biodegradability of ovalbumin after the crosslink-
ing process.
Uptake and delivery efficiency for OVA-NCs
Excellent ingestion efficiency of nanocarriers is a precon-
dition for an ideal therapeutic efficacy. Cell uptake efficiency
of the OVA-NCs in MCF-7 cells was investigated by using
confocal laser scanning microscopy (CLSM). As shown in
Figure S1a (Supporting Information), the red fluorescence
indicates an effective internalization of NCs in the cell.
Increased intensity of internalized OVA-NCs was observed
within 120 min (Figure S1b), suggesting an efficient uptake of
NCs by the cancer cells.
Following the endocytosis, the endosomal/lysosomal es-
cape is the most challenging step for an efficient delivery of
Table 1: Hydrodynamic diameter and z-potential of OVA-NCs containing
various combinations of Fe3O4 NPs, cisplatin, and photosensitizer NBS.







OVA-NC[a] Fe3O4 cisplatin NBS
Fe@OVA 1.70 0.15 312 29
FePt@OVA 2.06 0.19 0.20 316 31
FeNBS@OVA 2.13 0.19 0.20 331 35
FePtNBS@OVA 2.15 0.19 0.20 0.20 322 26
[a] Solid content of OVA-NCs measured by freeze drying the dispersions.
[b] Hydrodynamic diameter of OVA-NCs measured in water. [c] Zeta
potential measured in 1103m potassium chloride aqueous solution.
Figure 1. a) SEM and b) TEM images of OVA-NCs containing Fe3O4 NPs, cisplatin, and photosensitizer NBS. c) Hydrodynamic diameter of OVA-
NCs containing various combinations of functional payloads with time up to 30 days. d) Cumulative release of NBS without and with trypsin at
37 8C. Average results of three independent release experiments are reported.
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the payloads. The lysosomal imaging has been done to assess
the ability of the OVA-NCs for accelerating the lysosomal
escape of the payloads. Acridine orange (AO) was used to
characterize the lysosome membrane integrity. In the com-
plete lysosome, the AO is in a protonated oligomeric form,
showing a red fluorescence. In the cytoplasm, the AO is in
a deprotonated form as a monomer that shows green
fluorescence. Therefore, the intracellular distribution of AO
can be used to evaluate the lysosomal membrane integrity. As
shown in Figure 2, only light irradiation (G2) did not result in
damage of the lysosome membrane. We also clearly observed
red fluorescence in groups FePt@OVA (G3) and FePtNB-
S@OVA (G5), which showed that the cisplatin could not
induce the damage of lysosomemembrane without PDT, even
though the treatments caused slight cytotoxicity inferred from
the shrunk nuclei. In contrast, no red fluorescence was
observed for the group FeNBS@OVA+Light (G6) and
FePtNBS@OVA+Light (G7), indicating the disintegration
of lysosome membranes due to the phototoxicity of PDT
mediated by the NBS. Thus, the nanocapsules are able to
promote intracellular drug delivery to the nuclei by facilitat-
ing the lysosomal escape via PDT. More importantly, these
nanocapsules also showed an effective destruction of lyso-
somes under hypoxia environment (2% O2) by using
FePtNBS@OVA under light irradiation (G8). This result
proved the applicability of the OVA-NCs for enhanced
intracellular drug delivery in the hypoxia tumor microenvir-
onment.
Cisplatin has been well studied for inducing cell toxicity
via crosslinking of DNA in the nuclei. Therefore, the
accumulation of cisplatin in the nuclei determines its ther-
apeutic efficacy. The concentration of cisplatin in the nuclei
from different nanocapsule treatments has been quantified by
using inductively coupled plasma mass spectrometry (ICP-
MS; Figure S2). Overall, the nanocapsules (FePt@OVA and
FePtNBS@OVA) showed improved accumulation of cisplatin
in the nuclei in comparison with cells treated with free drug
(soluble cisplatin), which verified that the nanocarriers can
indeed improve the intracellular drug delivery efficiency.
After irradiation with a 660 nm light for 5 min, the Pt
accumulation in nuclei further increased (Figure S2). Com-
pared to the group treated with free cisplatin, there was an
increase of 2.5 times Pt concentration in the nuclei observed
for the group treated with FePtNBS@OVA+Light. Mean-
while, the light irradiation induced an increase of 1.8 times of
Pt accumulation in the nuclei compared to the same group in
the absence of light. Furthermore, the efficiency for nuclei
accumulation has been evaluated in cisplatin resistant cell line
MCF-7/DPP. As predicted, resistant cells show negligible
uptake for cisplatin due to the drug resistance. Moreover, the
cells present weak accumulation of FePt@OVA and FePt-
NBS@OVA in nuclei after incubation. In contrast, when the
FePtNBS@OVA+Light was applied, there was a significant
increase of Pt accumulation in the nuclei. This result can be
explained by the robust release of payloads from endosome or
lysosome mediated by PDT, which ensures a considerable
delivery amount of cisplatin to the nuclei. These results
demonstrate that the PDT based nanocapsules can effectively
enhance the intracellular delivery of cisplatin to the nuclei.
Assessment of ROS generation in normoxic and hypoxic
environments
The photosensitizer NBS can generate O2
C through type I
photoreactions and the O2
C can be further transformed to the
highly toxic COH (Scheme 1c). Firstly, the generation of O2C
was demonstrated using a O2
C fluorescence probe (DHR
123). The nanocapsules (FePtNBS@OVA) were firstly incu-
bated with trypsin to release NBS, followed by mixing with
DHR123. Red light irradiation of the solution led to
significantly fluorescence enhancement, indicating the pro-
duction of O2
C under light irradiation (Figure S3). We further
investigated the intracellular generation of O2
C and COH by
using a O2
C sensor dihydroethidium (DHE) and a COH sensor
hydroxyphenyl fluorescein (HPF), respectively. The MCF-7
cells were treated with both ROS sensors and the cell images
were obtained by CLSM (Figure 3). The fluorescence of both
DHE and HPF was not observed for the cells incubated with
FeNBS@OVA (G2). However, under 660 nm irradiation for
5 min, an obvious increase of the fluorescence intensity of
both DHE and HPF was detected in the group FeNBS@-
OVA+Light (G5), indicating the generation of O2
C and COH
by the nanocapsules under light irradiation. The FePt@OVA
(G3) and FePtNBS@OVA (G4) groups showed weak fluo-
rescence of DHE and HPF, which indicated that cisplatin can
induce the generation of O2
C in cells. The produced O2C was
partially converted to the COH. This is also true for the
experiments under light irradiation, where a higher fluores-
cence intensity of both DHE and HPF were observed for the
group FePtNBS@OVA+Light (G6) in comparison with that
of FeNBS@OVA+Light (G5) (Figures 3c,d). Based on this
result, we further added deferoxamine (DFOA) to the cells
for blocking the transformation of O2
C to the COH. As shown
in Figures 3c,d (G6 and G7), the DFOA decreased signifi-
Figure 2. CLSM images of AO staining for assessing the lysosomal
integrity. The green channel represents the fluorescence of AO
monomer (lex=488 nm, lem=500–550 nm), and the red channel
represents the fluorescence of the dimer of AO (lex=561 nm,
lem=600–630 nm). Scale bar=40 mm. Key: control (G1, no capsule),
light (G2), FePt@OVA (G3), FeNBS@OVA (G4), FePtNBS@OVA (G5),
FeNBS@OVA+Light (G6), FePtNBS@OVA+Light (G7), FePtNB-
S@OVA+Light (G8) hypoxia. Light irradiation was performed by
a 660 nm LED light (35 mWcm2, 4 min, 8.4 J cm2).
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cantly (70% decrease) the production of COHwith an increase
of the fluorescence intensity from the O2
C (FePtNBS@-
OVA+DFOA+Light, G7) compared to the group without
DFOA (G6). These results show that (i) cisplatin alone can
produce O2
C, and (ii) the NBS can produce O2C under light
irradiation. Therefore, combined cisplatin with NBS in the
nanocapsules enhanced the generation of O2
C, which can be
further transformed to the highly toxic COH to achieve
improved antitumor efficacy.
Hypoxia is a typical feature for the tumor microenviron-
ment, which restricts the application of PDT and undermines
the therapeutic efficacy of chemotherapy. Therefore, we
assessed here the generation of ROS by the nanocapsules
under hypoxic environment in order to evaluate their
therapeutic efficacy. Compared to the nanocapsules FePt-
NBS@OVA (G4, normoxia) in Figure 3, cisplatin-triggered
generation of O2
C can also be observed under hypoxic
conditions, although the fluorescence enhancement is lower
for the same sample FePtNBS@OVA (G2) in Figure 4a.
Similarly, treatment with FePtNBS@OVA+Light (G3) in-
duced significantly enhanced generation of O2
C (Fig-
ures 4a,b), which proved that the nanocapsules containing
NBS with light irradiation could effectively generate O2
C in
cells under hypoxic conditions. As expected, high concen-
trations of COH were also detected from G3 group (Fig-
ures 4c,d). To prove the synergistic effect of PDTand Fenton
reactions in hypoxic environment, we further added DFOA to
the cells, because DFOA can inhibit the Fenton reactions by
chelating Fe ions. As shown in Figure 4b, the generation of
O2
C in G4 was increased slightly, due to declined trans-
formation of O2
C. While, the presence of DFOA decreased
significantly (41% decrease) the production of COH com-
pared to the group without DFOA (G3) (Figure 4d). The
above results showed that the synergistic effect of PDT and
Fenton reactions efficiently enhanced the ROS generation
even under hypoxic conditions, thus making them ideal
nanosystems for in vivo anticancer treatment.
Live/death staining and apoptosis detection
Afterwards, a Calcein-AM/PI kit was applied to assess the
therapeutic efficacy of nanocapsules in vitro. The Calcein-
AM can mark living cells with green fluorescence, and PI can
track the dead cells with red fluorescence. In Figure S4d, theFigure 3. The detection of ROS generation in MCF-7 cells under
normoxia with different nanocapsule treatments by using CLSM.
Key: control (G1, without nanocapsule incubation), FeNBS@OVA
(G2), FePt@OVA (G3), FePtNBS@OVA (G4), FeNBS@OVA+Light
(G5), FePtNBS@OVA+Light (G6), FePtNBS@OVA+DFOA+Light
(G7). Light irradiation was carried out by a 660 nm LED light
(35 mWcm2, 4 min, 8.4 J cm2). The fluorescence of Hoechst 33342
was used to stain nuclei, with excitation at 405 nm and data collection
within the 420–480 nm range. Scale bar=40 mm. a) Generation of
O2
C ; red fluorescence was excited at 488 nm and collected at 590–
610 nm. b) Generation of COH; green fluorescence was excited at
488 nm and collected at 500–550 nm. c) Average fluorescence intensity
of DHE for the detection of O2
C. d) Average fluorescence intensity of
HPF for the detection of COH. Data are given as the mean  SD
(n=3).
Figure 4. a) Detection of O2
C (lex=488 nm, lem=590–610 nm) and
c) COH (lex=488 nm, lem=500–550 nm) generated in MCF-7 cells
under hypoxia with different nanocapsule treatments by using CLSM.
The fluorescence of Hoechst 33342 was excited at 405 nm and
collected at 420–480 nm. Scale bar=40 mm. b) The quantitative analy-
sis of fluorescence intensity of DHE for the detection of O2
C. d) The
quantitative analysis of fluorescence intensity of HPF for the detection
of COH. Key: control (G1), FePtNBS@OVA (G2), FePtNBS@OVA+
Light (G3), FePtNBS@OVA+DFOA+Light (G4). Light irradiation was
carried out by 660 nm LED light (35 mWcm2, 4 min, 8.4 J cm2). Data
are given as the mean  SD (n=3).
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red fluorescence dominates the image with negligible green
fluorescence when the cells were treated with the FePt-
NBS@OVA under light irradiation, indicating a remarkable
cytotoxicity. The cytotoxicity of FePtNBS@OVA+Light
(Figure 5d) was comparable to the non-carrier system
(mixture of Fe3O4/Pt/NBS, Figure 5e). This result showed
that (i) the reagents remained their functions after the
encapsulation procedure, and (ii) the nanocapsules effectively
delivered the reagents into the cells and further released them
in an active form based on the biodegradation of the proteins.
Compared with FePt@OVA, the PDT induced by NBS caused
superior therapeutic effect than the chemical toxicity induced
by cisplatin (Figures S4b,c). More importantly, the combina-
tion therapy showed higher efficacy for killing cancer cells
than the monotherapy (Figures S4b,c,d). Notably, the Fe@-
OVA did not show visible toxicity to the cells, which ensures
the biosafety of the nanocapsules.
We further studied the efficiency of OVA-NCs for
inhibiting the growth of cancer cells under hypoxia conditions.
The nanocapsules remained high therapeutic efficiency under
hypoxic condition (Figure S4i) in comparison with the effi-
ciency under normoxia condition (Figure S4d). The iron ions
catalyze the conversion of H2O2 to COH via a Fenton reaction.
To confirm this hypothesis, deferoxamine (DFOA) was added
to inhibit the catalysis reaction by the iron ions in order to
reduce the generation of COH. The decline of red fluorescence
indicated the decreased toxicity to the cells (Figure S4j). This
result validated the effectiveness of the Fenton reactions by
the iron ions for an enhanced therapeutic performance.
Annexin-FITC/PI kit was applied to study the pathways
for the cytotoxicity in different treatments by using flow
cytometry (Figure S5). Zone 1 represents the percentage of
normal cells; zone 2 and 3 are for the cells in early and late
apoptotic stage; zone 4 shows the proportion of necrotic cells.
The treatment with Fe@OVA showed no detectable toxicity
to the cells (Figure S5a). The toxic effect mediated by sole
chemotherapy and sole PDT induced late apoptosis for
36.4% (Figure S5b) and 75.0% (Figure S5d) of the cells,
respectively. Remarkably, up to 92.1% late cell apoptosis was
achieved in the FePtNBS@OVA+Light group (Figure S5e),
demonstrating that the combination of PDT with chemo-
therapy induced an enhanced toxicity towards cancer cells.
Moreover, when DFOA was added, the toxicity of the
combined therapy declined significantly (Figure S5c), which
indicated that the catalysis of Fe3O4 contributed to the
excellent anticancer effect. These results indicated that the
design of the nanocapsules achieved promising therapeutic
effect based on combined type I PDTand chemotherapy with
integrated tandem Fenton reactions.
Toxicity assessment
Furthermore, MTT (Thiazolyl Blue Tetrazolium Bro-
mide) was used to assess the toxicity with different treatments
on MCF-7 and 4T1 cells (Figure 5). The group for OVA and
Fe@OVA showed  100% viability at the concentration of
5.76 mgmL1 (Figure 5a). The group FePt@OVA resulted in
limited therapeutic efficiency. About 25% cells were killed
when the concentration of capsules was 5.76 mgmL1 (Fig-
ure 5b). The treatment based on FeNBS@OVAwithout light
showed negligible toxicity, while the irradiation at
35 mWcm2 for 4 min induced 40% cell death (Figure 5c).
Further introducing cisplatin to the PDT system led to a total
Figure 5. a–c) MCF-7 (upper row) and d–f) 4T1 (lower row) cell viability after different treatments and irradiation. Data are given as the mean 
SD (n=5). Horizontal axis is the concentration of OVA in (a—d) and (f), and of NBS in (e). Light irradiation was carried out by 660 nm light
(35 mWcm2, 4 min, 8.4 J cm2).
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cell death of 80% (Figure 5d). Moreover, the nanocapsules
demonstrated comparable therapeutic effects compared to
the mixture dose without carrier (Figure 5e). Addition of
DFOA also declined the toxicity to MCF-7 and 4T1 cells
(Figure 5 f), which indicated that the transformation from
O2
C to COH is vital for enhanced therapeutic efficiency. These
results showed that the co-delivery system possesses excellent
internalization efficiency and enhanced cytotoxicity.
Moreover, we evaluated the therapeutic effect of nano-
capsules in cisplatin resistant cells (MCF-7/DDP). The treat-
ment with FePt@OVA and FePtNBS@OVA showed no toxic
effect to the resistant cells (Figure 6a). Without light irradi-
ation, the treatment with FeNBS@OVA did not present
detectable toxicity to the cells (Figure 6b). However, when
the light illumination was applied, an increased cytotoxicity
was observed as the nanocapsules concentration increased.
The PDT/chemotherapy (FePtNBS@OVA) showed the high-
est toxicity (IC50  4 mgmL1) for the resistant cells (Fig-
ure 6d). The efficacy of the combination therapy was inves-
tigated under hypoxic and normoxic conditions. The nano-
capsules showed a concentration-dependent cell killing ability
in both environments (Figure 6c). Importantly, the significant
toxicity to the resistant cells was also observed under both
oxygen conditions (Figure 6d). The IC50 in normoxic environ-
ment is about 5.5 mgmL1, and 6.5 mgmL1 in hypoxic
environment, which means that FePtNBS@OVA can induce
significant toxicity towards the resistant cells in both nor-
moxic and hypoxic environments.
In vivo assessment of therapeutic efficacy
Tumor-bearing mice model was applied to assess the
therapeutic efficiency of the nanoformulations in vivo. Con-
sidering that it is difficult to cultivate tumors in normal mice
by using human breast cancer cells (MCF-7), we selected 4T1,
mice breast cancer cells, to establish the tumor-bearing mice
model. When the tumor volume reached approximately
100 mm3, we started the treatment by using the nanocapsules.
In fact, the internal part of solid tumors has a hypoxic
microenvironment, especially in the areas away from the
blood vessels (> 70 mm; Figure S6).[20,6a] As shown in Fig-
ure 7b, the FePtNBS@OVA nanocapsules presented prefer-
ential accumulation in the tumor site compared to the free
NBS (Figure 7a) due to the EPR effect. The nanocapsule
accumulation reached maximum in the tumor at 36 h, while
the free NBS was cleared from the blood circulation quickly.
Aweak accumulation of free NBS in tumor site was observed
(Figure 7a). In comparison, there was still considerable
retention of nanocapsules in the tumor until 48 h, which
guaranteed a sufficient time for the degradation of nano-
capsules and hence an effective release of functional pay-
loads. The results suggested that the nanocapsule carriers
effectively extended the blood circulation time of therapeutic
agents and increased accumulation in the tumor site. The
fluorescence images of isolated tissues for the two groups
further validated the preferable enrichment of nanocapsules
in the tumor (Figures 7c,d). The photographs of the tumor-
bearing mice 28 days after the treatment with different
formulations are shown in Figure 7e. The evolution of the
tumor volume was monitored during the treatment (Fig-
ure 7g). The loading of cisplatin led to a decrease of the tumor
volume (G4, G7). The light irradiation effectively improved
the therapeutic efficacy of PDT by comparing the results of
FeNBS@OVA without or with light irradiation (G5, G6).
Remarkably, the combined PDT and chemotherapy com-
pletely inhibited the growth of tumor (FePtNBS@OVA+
Light, G8). Additionally, the combination of free agents
(G3) was not able to inhibit the tumor growth, because small
molecules can be easily cleared from the blood circulation,
resulting in low tumor accumulation. The images of isolated
tumors in Figure 7 f also demonstrated that the treatment in
G8 can effectively inhibit the tumor growth.
The body weight changes of the mice were recorded over
the time range of treatment. No significant change of body
weight was observed for all the groups, indicating the
negligible systemic toxicity of the nanocapsules (Figure 7h).
The survival rate of mice over time was recorded. The groups
received the combined PDT and chemotherapy prolonged
lifespan of tumor-bearing mice (Figure 7 i). All mice survived
during a one-month monitoring period. The toxicity of
different treatments was also estimated via histological
analysis of the major organs (heart, liver, spleen, lung, and
kidney) of sacrificed mice after treatments (Figure S7). These
organs in all groups did not show any pathological tissue
damages or abnormality, verifying the high biosafety of the
OVA-NCs.
Figure 6. a) MTT test in cisplatin-resistant cells (MCF-7/DDP) from
the treatment with FePt@OVA and FePtNBS@OVA. b) MTT test in
MCF-7/DDP from the treatment with FeNBS@OVA and FeNBS@O-
VA+Light. c) MTT test in MCF-7 from the treatment with FePtNB-
S@OVA+Light in normoxic or hypoxic environment. d) MTT in MCF-
7/DDP from the treatment with FePtNBS@OVA+Light in normoxic or
hypoxic environments. Horizontal axis is the concentration of OVA in
all images in this Figure. Light irradiation was carried out by 660 nm
LED light (35 mWcm2, 4 min, 8.4 J cm2).
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Conclusion
A low O2 consumption PDT/chemotherapy system was
developed with integrated cascade Fenton reactions for
combined anticancer treatment by using biodegradable
ovalbumin nanocapsules as the nanocarriers. The core–shell
nanocapsules showed a high encapsulation efficiency for the
co-encapsulation of multiple functional payloads (photosen-
sitizer, cisplatin and Fe3O4 NPs) and their selective release
based on the biodegradation of the nanocapsule. The photo-
sensitizer NBS was able to generate ROS via type I photo-
reactions under red light (656 nm) even under a severe
hypoxic environment (2% O2), followed by the transforma-
tion of O2
C to highly toxic COH radicals via Fe2+-involved
Fenton reactions that are enabled by the dissolution of loaded
Fe3O4 NPs within the cancer cells. PDT also facilitated the
endosomal/lysosome escape of the payloads. Cisplatin gen-
erates O2C in the presence of NOX and SOD, therefore it
improves the PDT efficiency as an additional O2C source for
the production of toxic COH radicals. The developed nano-
medicine showed an improved anticancer efficiency via
combined type I PDT and chemotherapy with subsequent
Fenton reactions under both normoxic and hypoxic condi-
tions. Moreover, this nanoencapsulation strategy provides
a versatile platform for the flexible combination of different
therapies for biomedical applications.
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